Lung TransplantationNCT07525440
Neural Respiratory Drive Combined With Pro-Brain Natriuretic Peptide (Pro-BNP) as Predictor of Deterioration After Lung Transplantation
An observational study of Lung Transplantation, run by The First Affiliated Hospital of Guangzhou Medical University at 1 site in China.
Trial summary
Lung transplantation has become a promising therapeutic option for various end-stage lung diseases. However, many factors such as infection, graft rejection, airway complications would cause deterioration and shorten the survival time. Read more about this study
- Who is it for?
- Ages 20 to 85 years
- Conditions the study is for
- Lung Transplantation
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2016to 1 Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The patients with end-stage lung diseases referral to lung transplantation. Including chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasia
Who may be able to join
- The patients with end-stage lung diseases referral to lung transplantation,Including chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasia
Who cannot join
- Malignancy （2）Severe cardiovascular diseases （3）Neuromuscular and chest wall deformity (4) Cardiovascular instability (hypotension, arrhythmias, myocardial infarction) (5) Change in mental status; uncooperative patients （6）Renal failure and severe blood electrolyte disturbances
Trial locations and contacts
1 site in 1 country.
About this study
Lung transplantation has become a promising therapeutic option for various end-stage lung diseases. However, many factors such as infection, graft rejection, airway complications would cause deterioration and shorten the survival time. It is important to detect the deterioration early and receive treatment timely, which may enhance survival.
We hypothesis the decreased neural respiratory drive(NRD) would be increased in the deterioration due to the aggravation of lung. Furthermore, pro-Brain Natriuretic Peptide(pro-BNP) has been reported to be associated with greater mortality after lung transplantation.For this reason, we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration.
80 patients were recruited.They were end-stage lung disease patients admitted to hospital for lung transplantation. The NRD and pro-BNP were monitored before and after lung transplantation.we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration.
- Conditions
- Lung Transplantation
- Being tested
- No Intervention: Observational Cohort
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
no intervention
| Study group | Role | What they receive |
|---|---|---|
| the patients with end-stage lung diseases after lung transplantation | we investigated the NRD and pro-BNP before and after the patients with end-stage lung diseases lung transplantation and during deterioration. The relationship between NRD and pro-BNP and the deterioration were investigated Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
deterioration
deterioration rate
Measured: 6 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start1 Jan 2016
- Primary completion1 Feb 2026
- Study completion1 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung TransplantationStudies of the same condition, open and under way.
- More trials run by The First Affiliated Hospital of Guangzhou Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhang Jianheng, The First Affiliated Hospital of Guangzhou Medical University
- Investigators
- jianheng zhang, MD, Principal investigator, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07525440
- Sponsor's protocol ID
- YLS2024
- Other IDs
- 2020B11111340009
- Status last verified
- Apr 2026
- First submitted
- 6 Apr 2026
- Last updated
- 13 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The data is being analyzed.
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neural Respiratory Drive Combined With Pro-Brain Natriuretic Peptide (Pro-BNP) as Predictor of Deterioration After Lung Transplantation
- ClinicalTrials.gov ID
- NCT07525440
- Acronym / sponsor ID
- YLS2024
- Conditions
- Lung Transplantation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical UniversityUniversity, hospital or other
- Study start
- 1 Jan 2016 (actual)
- Primary completion
- 1 Feb 2026 (actual)
- Study completion
- 1 Feb 2026 (actual)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung transplantation has become a promising therapeutic option for various end-stage lung diseases. However, many factors such as infection, graft rejection, airway complications would cause deterioration and shorten the survival time. It is important to detect the deterioration early and receive treatment timely, which may enhance survival.
We hypothesis the decreased neural respiratory drive(NRD) would be increased in the deterioration due to the aggravation of lung. Furthermore, pro-Brain Natriuretic Peptide(pro-BNP) has been reported to be associated with greater mortality after lung transplantation.For this reason, we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration.
80 patients were recruited.They were end-stage lung disease patients admitted to hospital for lung transplantation. The NRD and pro-BNP were monitored before and after lung transplantation.we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| the patients with end-stage lung diseases after lung transplantation | – | Other: No Intervention: Observational Cohortwe investigated the NRD and pro-BNP before and after the patients with end-stage lung diseases lung transplantation and during deterioration. The relationship between NRD and pro-BNP and the deterioration were investigated |
Who may qualify
- Ages
- 20 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The patients with end-stage lung diseases referral to lung transplantation. Including chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasia
Key inclusion criteria (1 listed)
- The patients with end-stage lung diseases referral to lung transplantation,Including chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasia
Key exclusion criteria (1 listed)
- Malignancy （2）Severe cardiovascular diseases （3）Neuromuscular and chest wall deformity (4) Cardiovascular instability (hypotension, arrhythmias, myocardial infarction) (5) Change in mental status; uncooperative patients （6）Renal failure and severe blood electrolyte disturbances
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational Cohortno intervention | Other | the patients with end-stage lung diseases after lung transplantation |
Primary outcome
deterioration
Time frame: 6 years
deterioration rate
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
- Individual participant dataSharing planned: Undecided. The data is being analyzed.
Related trials for Lung Transplantation
RecruitingPhase 1
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
Lung Transplantation
Active, not recruitingPhase 1
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Pulmonary Arterial Hypertension
Active, not recruitingPhase 1/2
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
Recruiting
Multidisciplinary Non-Pharmacological Intervention to Improve Quality of Life in Solid Organ Transplant Recipients
Heart Transplant Patients, Kidney Transplant Patients
RecruitingObservational study
Trifecta-Lung cfDNA-MMDx Study
Lung Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
jianheng zhang, MD principal investigator
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Transplantation, run by The First Affiliated Hospital of Guangzhou Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
deterioration (time frame: 6 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.